Condition category
Musculoskeletal Diseases
Date applied
15/01/2019
Date assigned
15/08/2019
Last edited
15/08/2019
Prospective/Retrospective
Retrospectively registered
Overall trial status
Ongoing
Recruitment status
Recruiting

Plain English Summary

Background and study aims
Osteoporosis is a condition that weakens bones, making them fragile and more likely to break. It is a condition that develops slowly over several years and is often only diagnosed when a minor fall or sudden impact causes a bone break (or fracture). Osteoporosis particularly affects the spine and hips, resulting in breaks of the bone in these areas. Whilst treatment of osteoporosis is now quite straightforward, detection is difficult. In the UK, osteoporosis causes 200,000 fractures of the spine yearly in women and men. The pain of a small spine fracture can feel like ordinary backache, and as a result patients are often left undiagnosed, so many small fractures are common. This eventually leads to poorer mobility and increased pain for the sufferer. The aim of this study is to find out whether it is possible to identify osteoporosis earlier, leading to improved treatment and better outcomes. To do this the researchers will be looking at special scans called CT scans (computerised tomography) that patients are already having for various reasons, and using some new software that has been developed to make more accurate diagnosis of osteoporosis and bone fractures. A CT scan uses x-rays and a computer to create images of the inside of the body; two million are performed each year in the UK, often for abdominal or pelvic problems. In this study, CT images are reviewed using a new software to identify osteoporosis enabling early treatment and potentially preventing future fractures. This new technology makes it simple to measure a patient’s bone density quickly and identify vertebral fractures from CT images of a patient's torso or pelvis. Bone density measurements of the spine and hips are performed on images acquired from any CT scanner. This study is a feasibility study to see if it is realistic to develop into a national trial, so the researchers will be looking at how well they can recruit participants to the study, and as they hope to follow up with a questionnaire after one year, they will also be looking at how many people stay in the study, or drop out.

Who can participate?
Women aged 65 - 90 and men aged 75 - 90 years who are undergoing a CT scan that includes the pelvis

What does the study involve?
If someone is attending a CT Department for a scan in a participating hospital and is eligible to be part of the study (that is, within the correct age range and having a scan that includes the pelvis), they will be approached by a member of the research team at the local hospital and asked if they would like to be part of the study. If they are interested in being part of the study the patient will be asked to complete a Bone Health Questionnaire and sign a consent form. The patient will also be asked for their contact details so that the researchers can post out a questionnaire in about 2 months’ time, and later at about 1 year. The answers of the Bone Health Questionnaire will be used to calculate the chance of that patient breaking a bone during the next 10 years. If the answers suggest an increased risk, they will be randomly allocated to one of three study groups. In all three groups bone density is measured and the scans are studied for evidence of small fractures; in some cases this will happen immediately and in others in 12 months’ time (there will not be a difference in long-term outcomes for the patient if they are in the group with delayed review of the scan). The groups will be chosen at random (like tossing a coin to make a decision) and NOT by the doctor. If answers suggest that the chances of breaking a bone are low, there will be no need to check bone health straight away. Once the CT scans are looked at by the specialist team in Cambridge, a report will be sent to GPs with results and guidance as to any treatment. Two questionnaires are sent out to participants – one after about 2 months, and one at one year. These will ask about any medication that may be prescribed for bone health and how participants are managing in their day to day life; they should take about 15 minutes to complete. A small number of patients will be asked if they would agree to telling us about their experience of the study; this can be by face to face discussion, or over the phone.

What are the possible benefits and risks of participating?
Possible benefits are that patients may receive earlier diagnosis and treatment of osteoporosis. There are no risks to being part of this study.

Where is the study run from?
The study is run jointly by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. Scans will be looked at in Cambridge, and all co-ordination of the study will be from there. There are other sites participating in this study: Addenbrooke’s Hospital, Peterborough City Hospital, Lister Hospital, West Suffolk Hospital and Bedford Hospital.

When is the study starting and how long is it expected to run for?
September 2019 to August 2021

Who is funding the study?
National Institute for Health Research (UK)

Who is the main contact?
Karen Willoughby
kw369@medschl.cam.ac.uk

Trial website

http://www.med.cam.ac.uk/poole/phoenix/

Contact information

Type

Public

Primary contact

Mrs Karen Willoughby

ORCID ID

Contact details

Clinical Trial Manager
University of Cambridge
Dept of Bone Health
Box 157
Level 5
Addenbrooke's Hospital
Hills Road
Cambridge
CB2 0QQ
United Kingdom
+44 (0)1223 217580
kw369@medschl.cam.ac.uk

Type

Scientific

Additional contact

Dr Kenneth Poole

ORCID ID

Contact details

Consultant in Rheumatology & Metabolic Bone Disease
Addenbrooke's Hospital
Hills Road
Cambridge
CB2 0QQ
United Kingdom

Additional identifiers

EudraCT number

Nil known

ClinicalTrials.gov number

Nil known

Protocol/serial number

PB-PG-0816-2007; CPMS: 41112

Study information

Scientific title

PHOENIX-f: a feasibility study for early identification of vertebral fractures and osteoporosis by opportunistically using CT scans undertaken for other purposes

Acronym

PHOENIX-f

Study hypothesis

It is hypothesised there will be value in early diagnosis and treatment of osteoporosis, through fractures prevented, societal and social burden and reduced health costs. The current usual care for case-finding osteoporosis in older people is for the GP to ask their patient to complete a FRAX questionnaire. The responses to these 11 questions regarding fracture risk factors are then entered by the GP into an online calculator which indicates whether a DXA scan should be requested. Uptake of case finding is low and there is no national mandate for screening. High-risk patients are referred for a DXA scan and treatment is offered if the bone mineral density (BMD) is low and/or fracture risk sufficiently high. Vertebral fractures are rarely detected in usual care even though they (alongside hip fractures) cause the biggest burden to patients and the health service. The expectation is that targeted screening will improve upon usual care and appropriately increase the diagnostic rate.

There are several reasons for opportunistic osteoporosis screening during a CT scan:
1. CT attenders are a high-risk population; >30% of these older adults have undiagnosed vertebral fractures or osteoporosis that can be effectively treated once identified
2. The PHOENIX pathway allows us to diagnose osteoporosis on scans already done, without additional x-rays/hospital visits
3. Opportunistic case-finding is recommended by NICE
4. Screening is effective at reducing hip fractures

Ethics approval

Approved 28/07/2019, East of England - Cambridge East Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK; Tel: +44 (0)20 7104 8096; Email: nrescommittee.eastofengland-cambridgeeast@nhs.net), REC ref: 19/EE/0176

Study design

Randomised controlled non-blinded multi-centre feasibility study

Primary study design

Interventional

Secondary study design

Feasibility study for future intended clinical randomised controlled trial

Trial setting

Hospitals

Trial type

Diagnostic

Patient information sheet

Not available in web format, please use contact details to request a participant information sheet

Condition

Osteoporosis

Intervention

Intervention is FRAX questionnaire and review of CT scans repurposed to look at for vertebral fractures and early osteoporosis using software. GPs will be informed of analysis immediately in Group 1, in Group 2 GP will receive only FRAX calculation results and in group 3 no results will be communicated. To avoid any disadvantage, all CT scans of participating individuals will be analysed and results sent after one year to GPs if they are in Groups 2 & 3.

Intervention type

Other

Phase

Drug names

Primary outcome measure

1. Recruitment rate recorded as the number of eligible participants who consent to participate in the study in 10 months
2. Attrition rate recorded as the number of participants who consent to participate that remain in the study until the end of follow up one year after recruitment

Secondary outcome measures

There are no secondary outcome measures

Overall trial start date

01/09/2018

Overall trial end date

31/08/2021

Reason abandoned (if study stopped)

Eligibility

Participant inclusion criteria

1. Attend one of five participating radiology departments
2. Volunteers able to provide informed consent
3. Women aged ≥65 - 90 and men aged ≥75 – 90 years inclusive
4. Attending for CT, for any clinical reason, where the spine and/or hips are visible in the scan images

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

Planned Sample Size: 375; UK Sample Size: 375

Participant exclusion criteria

1. Aged > 90
2. Bilateral metalwork in hips
3. Unable to provide valid consent
4. Known to be receiving prescription treatment for osteoporosis other than calcium/vitamin D (i.e. bisphosphonate drug, strontium ranelate, denosumab, raloxifene or teriparatide)
5. Prone CT scan

Recruitment start date

01/05/2019

Recruitment end date

01/03/2020

Locations

Countries of recruitment

United Kingdom

Trial participating centre

Cambridge University Hospitals NHS Foundation Trust
Addenbrooke's Hospital
Cambridge
CB2 0QQ
United Kingdom

Trial participating centre

North West Anglia NHS Trust
Hinchingbrooke Hospital
Huntingdon
PE29 6NT
United Kingdom

Trial participating centre

East & N Herts NHS Trust
Lister Hospital
Stevena
SG1 4AB
United Kingdom

Trial participating centre

West Suffolk NHS Foundation Trust
West Suffolk Hospital
Bury St Edmunds
IP33 2QZ
United Kingdom

Trial participating centre

Bedford Hospital
Kempston Rd
Bedford
MK42 9DJ
United Kingdom

Sponsor information

Organisation

Cambridge University NHS Foundation Trust

Sponsor details

Addenbrooke's Hospital
Hills Road
Cambridge
CB2 0QQ
United Kingdom

Sponsor type

Hospital/treatment centre

Website

https://www.cuh.nhs.uk/addenbrookes-hospital

Funders

Funder type

Government

Funder name

National Institute for Health Research

Alternative name(s)

NIHR

Funding Body Type

government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

On study completion the data will be analysed and report submitted to the funding body to indicate feasibility of progressing to a full trial.

IPD sharing statement
The data sharing plans for the current study are unknown and will be made available at a later date.

Intention to publish date

31/08/2021

Participant level data

To be made available at a later date

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

15/08/2019: Uploaded protocol Version 1.2, 1 July 2019 (not peer reviewed). 05/08/2019: Trial's existence confirmed by the NIHR.